Condition: Acute Myeloid Leukemia (AML) · Sponsor: Bio-Path Holdings, Inc.
The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission \[CR\], Complete Remission with incomplete hematologic recovery \[CRi\], Complete Remission with partial hematologic recovery \[CRh\], than venetoclax plus decitabine alone (by historical comparison) in participants with untreated AML that cannot or elect not to be treated with more intensive chemotherapy; (2) whether BP1001-based treatment provides greater efficacy (CR, CRi, CRh) than intensive chemotherapy (by historical comparison) in participants with refractory/relapsed AML.
This description comes directly from the study's public registry record.
Maro Ohanian, DO · 713-792-2631 · mohanian@mdanderson.org
Always discuss trial participation with your own doctor first.
| UCLA Medical Center | Los Angeles, California, United States | Recruiting |
| Georgia Cancer Center at Augusta University | Augusta, Georgia, United States | Recruiting |
| University of Kansas Cancer Center | Fairway, Kansas, United States | Recruiting |
| New Jersey Hematology Oncology Associates | Brick, New Jersey, United States | Terminated |
| Laura & Isaac Pe lmutter Cancer Center at NYU Langone Health | New York, New York, United States | Recruiting |
| Weill Cornell Medical College - New York - Presbyterian Hospital | New York, New York, United States | Recruiting |
| University of Texas M.D. Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Baylor Scott & White Research Institute | Temple, Texas, United States | Terminated |
| West Virginia University/Mary Babb Randolph Cancer Center | Morgantown, West Virginia, United States | Terminated |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02781883